Global ADC Drug CDMO Service 麻豆原创 Growth (Status and Outlook) 2024-2030

Publication ID:

LPI10249380

Publication Date:

October 14, 2024

Pages:

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

IT Services [2]

Software [3]

Computing & Electronics [4]

Description:

ADC drugs, also known as antibody drug coupling agents, work by coupling small molecule drugs with antibodies through linkers to form drugs. These drugs combine the high targeting ability of antibodies with the strong killing power of chemical drugs, and are considered the most promising next-generation antibody technology. To reduce research and development costs, most ADC drug development worldwide chooses outsourcing, leveraging CDMO companies to enter clinical and market more quickly. CDMO services refer to pharmaceutical and biotechnology companies outsourcing the research and production of their drugs or biological products to professional CDMO companies. These CDMO companies provide a range of services, including but not limited to drug synthesis, chemical and biological analysis, formulation development, clinical production, and commercial production. The core of CDMO services lies in its ability to customize and specialize, which can meet the specific needs of different customers at different stages.
The global ADC Drug CDMO Service market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.
LPI (publisher)' newest research report, the 鈥淎DC Drug CDMO Service Industry Forecast鈥� looks at past sales and reviews total world ADC Drug CDMO Service sales in 2022, providing a comprehensive analysis by region and market sector of projected ADC Drug CDMO Service sales for 2023 through 2029. With ADC Drug CDMO Service sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world ADC Drug CDMO Service industry.
This Insight Report provides a comprehensive analysis of the global ADC Drug CDMO Service landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on ADC Drug CDMO Service portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global ADC Drug CDMO Service market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for ADC Drug CDMO Service and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global ADC Drug CDMO Service.
United States market for ADC Drug CDMO Service is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for ADC Drug CDMO Service is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for ADC Drug CDMO Service is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key ADC Drug CDMO Service players cover WuXi XDC, Lonza, Merck, Axplora, Catalent, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of ADC Drug CDMO Service market by product type, application, key players and key regions and countries.
Segmentation by Type:
Antibody
Linker and Payload
Other
Segmentation by Application:
Small and Medium-sized Pharmaceutical Companies
Large Pharmaceutical Companies
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
Segmentation by Type:
Antibody
Linker and Payload
Other
Segmentation by Application:
Small and Medium-sized Pharmaceutical Companies
Large Pharmaceutical Companies
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
WuXi XDC
Lonza
Merck
Axplora
Catalent
Abbvie
MabPlex International
TOT Biopharm
Zencore Biologics
Healsun Biopharm

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global ADC Drug CDMO Service 麻豆原创 Size 2019-2030
2.1.2 ADC Drug CDMO Service 麻豆原创 Size CAGR by Region (2019 VS 2023 VS 2030)
2.1.3 World Current & Future Analysis for ADC Drug CDMO Service by Country/Region, 2019, 2023 & 2030
2.2 ADC Drug CDMO Service Segment by Type
2.2.1 Antibody
2.2.2 Linker and Payload
2.2.3 Other
2.3 ADC Drug CDMO Service 麻豆原创 Size by Type
2.3.1 ADC Drug CDMO Service 麻豆原创 Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global ADC Drug CDMO Service 麻豆原创 Size 麻豆原创 Share by Type (2019-2024)
2.4 ADC Drug CDMO Service Segment by Application
2.4.1 Small and Medium-sized Pharmaceutical Companies
2.4.2 Large Pharmaceutical Companies
2.5 ADC Drug CDMO Service 麻豆原创 Size by Application
2.5.1 ADC Drug CDMO Service 麻豆原创 Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global ADC Drug CDMO Service 麻豆原创 Size 麻豆原创 Share by Application (2019-2024)
3 ADC Drug CDMO Service 麻豆原创 Size by Player
3.1 ADC Drug CDMO Service 麻豆原创 Size 麻豆原创 Share by Player
3.1.1 Global ADC Drug CDMO Service Revenue by Player (2019-2024)
3.1.2 Global ADC Drug CDMO Service Revenue 麻豆原创 Share by Player (2019-2024)
3.2 Global ADC Drug CDMO Service Key Players Head office and Products Offered
3.3 麻豆原创 Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 ADC Drug CDMO Service by Region
4.1 ADC Drug CDMO Service 麻豆原创 Size by Region (2019-2024)
4.2 Global ADC Drug CDMO Service Annual Revenue by Country/Region (2019-2024)
4.3 Americas ADC Drug CDMO Service 麻豆原创 Size Growth (2019-2024)
4.4 APAC ADC Drug CDMO Service 麻豆原创 Size Growth (2019-2024)
4.5 Europe ADC Drug CDMO Service 麻豆原创 Size Growth (2019-2024)
4.6 Middle East & Africa ADC Drug CDMO Service 麻豆原创 Size Growth (2019-2024)
5 Americas
5.1 Americas ADC Drug CDMO Service 麻豆原创 Size by Country (2019-2024)
5.2 Americas ADC Drug CDMO Service 麻豆原创 Size by Type (2019-2024)
5.3 Americas ADC Drug CDMO Service 麻豆原创 Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC ADC Drug CDMO Service 麻豆原创 Size by Region (2019-2024)
6.2 APAC ADC Drug CDMO Service 麻豆原创 Size by Type (2019-2024)
6.3 APAC ADC Drug CDMO Service 麻豆原创 Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe ADC Drug CDMO Service 麻豆原创 Size by Country (2019-2024)
7.2 Europe ADC Drug CDMO Service 麻豆原创 Size by Type (2019-2024)
7.3 Europe ADC Drug CDMO Service 麻豆原创 Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa ADC Drug CDMO Service by Region (2019-2024)
8.2 Middle East & Africa ADC Drug CDMO Service 麻豆原创 Size by Type (2019-2024)
8.3 Middle East & Africa ADC Drug CDMO Service 麻豆原创 Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Global ADC Drug CDMO Service 麻豆原创 Forecast
10.1 Global ADC Drug CDMO Service Forecast by Region (2025-2030)
10.1.1 Global ADC Drug CDMO Service Forecast by Region (2025-2030)
10.1.2 Americas ADC Drug CDMO Service Forecast
10.1.3 APAC ADC Drug CDMO Service Forecast
10.1.4 Europe ADC Drug CDMO Service Forecast
10.1.5 Middle East & Africa ADC Drug CDMO Service Forecast
10.2 Americas ADC Drug CDMO Service Forecast by Country (2025-2030)
10.2.1 United States 麻豆原创 ADC Drug CDMO Service Forecast
10.2.2 Canada 麻豆原创 ADC Drug CDMO Service Forecast
10.2.3 Mexico 麻豆原创 ADC Drug CDMO Service Forecast
10.2.4 Brazil 麻豆原创 ADC Drug CDMO Service Forecast
10.3 APAC ADC Drug CDMO Service Forecast by Region (2025-2030)
10.3.1 China ADC Drug CDMO Service 麻豆原创 Forecast
10.3.2 Japan 麻豆原创 ADC Drug CDMO Service Forecast
10.3.3 Korea 麻豆原创 ADC Drug CDMO Service Forecast
10.3.4 Southeast Asia 麻豆原创 ADC Drug CDMO Service Forecast
10.3.5 India 麻豆原创 ADC Drug CDMO Service Forecast
10.3.6 Australia 麻豆原创 ADC Drug CDMO Service Forecast
10.4 Europe ADC Drug CDMO Service Forecast by Country (2025-2030)
10.4.1 Germany 麻豆原创 ADC Drug CDMO Service Forecast
10.4.2 France 麻豆原创 ADC Drug CDMO Service Forecast
10.4.3 UK 麻豆原创 ADC Drug CDMO Service Forecast
10.4.4 Italy 麻豆原创 ADC Drug CDMO Service Forecast
10.4.5 Russia 麻豆原创 ADC Drug CDMO Service Forecast
10.5 Middle East & Africa ADC Drug CDMO Service Forecast by Region (2025-2030)
10.5.1 Egypt 麻豆原创 ADC Drug CDMO Service Forecast
10.5.2 South Africa 麻豆原创 ADC Drug CDMO Service Forecast
10.5.3 Israel 麻豆原创 ADC Drug CDMO Service Forecast
10.5.4 Turkey 麻豆原创 ADC Drug CDMO Service Forecast
10.6 Global ADC Drug CDMO Service Forecast by Type (2025-2030)
10.7 Global ADC Drug CDMO Service Forecast by Application (2025-2030)
10.7.1 GCC Countries 麻豆原创 ADC Drug CDMO Service Forecast
11 Key Players Analysis
11.1 WuXi XDC
11.1.1 WuXi XDC Company Information
11.1.2 WuXi XDC ADC Drug CDMO Service Product Offered
11.1.3 WuXi XDC ADC Drug CDMO Service Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.1.4 WuXi XDC Main Business Overview
11.1.5 WuXi XDC Latest Developments
11.2 Lonza
11.2.1 Lonza Company Information
11.2.2 Lonza ADC Drug CDMO Service Product Offered
11.2.3 Lonza ADC Drug CDMO Service Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.2.4 Lonza Main Business Overview
11.2.5 Lonza Latest Developments
11.3 Merck
11.3.1 Merck Company Information
11.3.2 Merck ADC Drug CDMO Service Product Offered
11.3.3 Merck ADC Drug CDMO Service Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.3.4 Merck Main Business Overview
11.3.5 Merck Latest Developments
11.4 Axplora
11.4.1 Axplora Company Information
11.4.2 Axplora ADC Drug CDMO Service Product Offered
11.4.3 Axplora ADC Drug CDMO Service Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.4.4 Axplora Main Business Overview
11.4.5 Axplora Latest Developments
11.5 Catalent
11.5.1 Catalent Company Information
11.5.2 Catalent ADC Drug CDMO Service Product Offered
11.5.3 Catalent ADC Drug CDMO Service Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.5.4 Catalent Main Business Overview
11.5.5 Catalent Latest Developments
11.6 Abbvie
11.6.1 Abbvie Company Information
11.6.2 Abbvie ADC Drug CDMO Service Product Offered
11.6.3 Abbvie ADC Drug CDMO Service Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.6.4 Abbvie Main Business Overview
11.6.5 Abbvie Latest Developments
11.7 MabPlex International
11.7.1 MabPlex International Company Information
11.7.2 MabPlex International ADC Drug CDMO Service Product Offered
11.7.3 MabPlex International ADC Drug CDMO Service Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.7.4 MabPlex International Main Business Overview
11.7.5 MabPlex International Latest Developments
11.8 TOT Biopharm
11.8.1 TOT Biopharm Company Information
11.8.2 TOT Biopharm ADC Drug CDMO Service Product Offered
11.8.3 TOT Biopharm ADC Drug CDMO Service Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.8.4 TOT Biopharm Main Business Overview
11.8.5 TOT Biopharm Latest Developments
11.9 Zencore Biologics
11.9.1 Zencore Biologics Company Information
11.9.2 Zencore Biologics ADC Drug CDMO Service Product Offered
11.9.3 Zencore Biologics ADC Drug CDMO Service Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.9.4 Zencore Biologics Main Business Overview
11.9.5 Zencore Biologics Latest Developments
11.10 Healsun Biopharm
11.10.1 Healsun Biopharm Company Information
11.10.2 Healsun Biopharm ADC Drug CDMO Service Product Offered
11.10.3 Healsun Biopharm ADC Drug CDMO Service Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.10.4 Healsun Biopharm Main Business Overview
11.10.5 Healsun Biopharm Latest Developments
12 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.